Our science
The world’s best preclinical neuroscience
For more than 30 years, in collaboration with some of the best partners in the world, Atuka’s scientists have continued to advance both knowledge and research techniques in the field of Parkinson’s disease and beyond. This has led to the development of the broadest range of preclinical animal models for Parkinson’s disease.
White papers and Discovery Series
-

Beyond the Canonical Motor Syndrome: Non-motor and Non-canonical Features of Parkinson’s Disease
Symptom architecture, circuit-state instability, and the design of translational preclinical models.
-

Discovery Series #3 – LRRK2
Emerging Targets in Parkinson’s Disease: Leucine-rich repeat kinase 2 (LRRK2)-targeted therapies for the treatment of Parkinson’s disease
-

Discovery Series #2 – BDNF/TrkB
Emerging targets in Parkinson’s Disease: The Potential of BDNF/TrkB Pathway Modulation
-

Redefining Parkinson’s Disease: Biological Classification and the Future of Therapeutics
How biomarker-driven frameworks like SynNeurGe and NSD-ISS are reshaping our understanding of PD.
-

Discovery Series #1 – D1 PAM
Emerging targets in Parkinson’s Disease: The Potential of D1 Dopamine Receptor Positive Allosteric Modulators
-

Optimizing Preclinical Studies for Parkinson’s Disease Therapeutics
A strategic approach to animal model selection
Behind the science
-

Aligning in vivo models of Parkinson’s disease with biological classifications
A free short video lecture from Atuka’s Chief Innovation Officer Dr. Patrick Howson, on the reasons why Parkinson’s research has delivered symptomatic therapies but no disease-modifying ones, and how biological…
-

The importance of data management in ensuring the integrity of biomedical research
From data handling and analysis to transparent reporting protocols, EQIPD guidelines are helping to ensure researchers generate more robust and reliable data.
-

Towards a cure, through collaboration and clarity: Perspectives from the 2025 MJFF Therapeutics Conference
How researchers, clinicians, and companies are reading the current moment in Parkinson’s Research.
-

A quality system that boosts both research integrity and innovation
Unlike other quality systems, EQIPD has been designed to spur innovation in research without sacrificing rigor.
Published papers
Atuka’s scientists have been publishing groundbreaking neuroscience research for many decades, often in collaboration with other renowned leaders in our field. The peer-reviewed papers collected below track the evolution of both our ongoing research and the field more broadly.

Talk to our experts
Advance your therapeutic program
Get the latest science from Atuka
Sign up to receive our quarterly newsletter featuring the latest developments in Parkinson’s disease research.










